$50.04
-0.03-0.06%
Last update: Nov 10, 4:43 AM
CRISPR Therapeutics AG
CRSPNASDAQ
The average analyst price target for CRISPR Therapeutics is $71.74, 43.4% above the current price. Of 24 analysts, 13 rate it Buy, 10 Hold and 1 Sell. Targets range from $32 to $120. The latest change came on Nov 4, 2026, when Citigroup raised its price target on CRISPR Therapeutics from $88 to $90 and kept a Buy rating.
Price Target Range — 12 Quarters
Analyst Consensus — 24 Analysts
Rating Trend — Last 9 Months
